{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:07:08Z","timestamp":1781712428541,"version":"3.54.5"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,22]]},"DOI":"10.7759\/cureus.95128","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:23:11Z","timestamp":1761124991000},"source":"Crossref","is-referenced-by-count":1,"title":["Optimizing Transarterial Chemoembolization in Hepatocellular Carcinoma: Current Strategies, Innovations, and Future Directions"],"prefix":"10.7759","author":[{"given":"Jeraun","family":"Dolphin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zubillaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qazi Muhammad","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrah Fathima Karimbanakkal","family":"Edakkattu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarati","family":"Sapkota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anum","family":"Naimat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aye","family":"Nyein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Confidence Obianuju","family":"Okorie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aabind  S","family":"Dev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123202","article-title":"Pathogenesis and current treatment strategies of hepatocellular carcinoma","volume":"10","author":"T\u00fcmen D","year":"2022","unstructured":"T\u00fcmen D, Heumann P, G\u00fclow K, Demirci CN, Cosma LS, M\u00fcller M, Kandulski A. Pathogenesis and current treatment strategies of hepatocellular carcinoma. Biomedicines. 2022, 10:3202. 10.3390\/biomedicines10123202","journal-title":"Biomedicines"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01014-3","article-title":"Therapeutic options in hepatocellular carcinoma: a comprehensive review","volume":"23","author":"Suresh D","year":"2023","unstructured":"Suresh D, Srinivas AN, Prashant A, Harikumar KB, Kumar DP. Therapeutic options in hepatocellular carcinoma: a comprehensive review. Clin Exp Med. 2023, 23:1901-16. 10.1007\/s10238-023-01014-3","journal-title":"Clin Exp Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2024.04.002","article-title":"Multimodal treatment confers best overall survival results in patients with huge hepatocellular carcinoma: a systematic review and network meta-analysis","volume":"26","author":"Chierici A","year":"2024","unstructured":"Chierici A, El Zibawi M, Liddo G, Anty R, Granieri S, Chevallier P, Iannelli A. Multimodal treatment confers best overall survival results in patients with huge hepatocellular carcinoma: a systematic review and network meta-analysis. HPB (Oxford). 2024, 26:895-902. 10.1016\/j.hpb.2024.04.002","journal-title":"HPB (Oxford)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251316663","article-title":"Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients","volume":"17","author":"Arendt N","year":"2025","unstructured":"Arendt N, Kopsida M, Khaled J, Sj\u00f6blom M, Heindryckx F. Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients. Ther Adv Med Oncol. 2025, 17:17588359251316663. 10.1177\/17588359251316663","journal-title":"Ther Adv Med Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100578","article-title":"What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association","volume":"4","author":"Allaire M","year":"2022","unstructured":"Allaire M, Bruix J, Korenjak M, et al.. What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association. JHEP Rep. 2022, 4:100578. 10.1016\/j.jhepr.2022.100578","journal-title":"JHEP Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.27189","article-title":"Prediction model for intermediate-stage hepatocellular carcinoma response to transarterial chemoembolization","volume":"52","author":"Jia F","year":"2020","unstructured":"Jia F, Wu B, Yan R, Li L, Wang K, Han D. Prediction model for intermediate-stage hepatocellular carcinoma response to transarterial chemoembolization. J Magn Reson Imaging. 2020, 52:1657-67. 10.1002\/jmri.27189","journal-title":"J Magn Reson Imaging"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-022-03141-y","article-title":"Comparison of the efficacy among transcatheter arterial chemoembolization (TACE)-radiofrequency ablation plus apatinib, Tace plus apatinib, and Tace alone for hepatocellular carcinoma: a retrospective study","volume":"45","author":"Ouyang T","year":"2022","unstructured":"Ouyang T, Cao Y, Chen L, Zheng C. Comparison of the efficacy among transcatheter arterial chemoembolization (TACE)-radiofrequency ablation plus apatinib, Tace plus apatinib, and Tace alone for hepatocellular carcinoma: a retrospective study. Cardiovasc Intervent Radiol. 2022, 45:780-90. 10.1007\/s00270-022-03141-y","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-021-02451-8","article-title":"The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis","volume":"20","author":"Gong A","year":"2022","unstructured":"Gong A, Li X. The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis. World J Surg Oncol. 2022, 20:69. 10.1186\/s12957-021-02451-8","journal-title":"World J Surg Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_2226_24","article-title":"Transarterial chemoembolization combined with percutaneous ethanol injection for the treatment of hepatocellular carcinoma at high-risk areas","volume":"21","author":"Feng W","year":"2025","unstructured":"Feng W, Guo Y, Lu S, Yin Y, Xue T, Li Z. Transarterial chemoembolization combined with percutaneous ethanol injection for the treatment of hepatocellular carcinoma at high-risk areas. J Cancer Res Ther. 2025, 21:395-400. 10.4103\/jcrt.jcrt_2226_24","journal-title":"J Cancer Res Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41943","article-title":"Evaluation of the safety and efficacy of conventional transarterial chemoembolization (cTACE) and drug-eluting bead (DEB)-TACE in the management of unresectable hepatocellular carcinoma: a systematic review","volume":"15","author":"Ayyub J","year":"2023","unstructured":"Ayyub J, Dabhi KN, Gohil NV, et al.. Evaluation of the safety and efficacy of conventional transarterial chemoembolization (cTACE) and drug-eluting bead (DEB)-TACE in the management of unresectable hepatocellular carcinoma: a systematic review. Cureus. 2023, 15:e41943. 10.7759\/cureus.41943","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246172","article-title":"Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: A systematic review and meta-analysis","volume":"13","author":"Bzeizi KI","year":"2021","unstructured":"Bzeizi KI, Arabi M, Jamshidi N, et al.. Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Cancers (Basel). 2021, 13:6172. 10.3390\/cancers13246172","journal-title":"Cancers (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang Y","year":"2020","unstructured":"Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci. 2020, 21:8165. 10.3390\/ijms21218165","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v10.i7.485","article-title":"Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"10","author":"Hatanaka T","year":"2018","unstructured":"Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Hepatol. 2018, 10:485-95. 10.4254\/wjh.v10.i7.485","journal-title":"World J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12622","article-title":"Bridging and downstaging with TACE in early and intermediate stage hepatocellular carcinoma: Predictors of receiving a liver transplant","volume":"7","author":"Yin C","year":"2023","unstructured":"Yin C, Armstrong S, Shin R, et al.. Bridging and downstaging with TACE in early and intermediate stage hepatocellular carcinoma: Predictors of receiving a liver transplant. Ann Gastroenterol Surg. 2023, 7:295-305. 10.1002\/ags3.12622","journal-title":"Ann Gastroenterol Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132430","article-title":"Transarterial chemoembolization treatment paradigms for hepatocellular carcinoma","volume":"16","author":"Fite EL","year":"2024","unstructured":"Fite EL, Makary MS. Transarterial chemoembolization treatment paradigms for hepatocellular carcinoma. Cancers (Basel). 2024, 16:2430. 10.3390\/cancers16132430","journal-title":"Cancers (Basel)"},{"key":"ref17","article-title":"Recent progress in treatment of hepatocellular carcinoma","volume":"10","author":"Chen Z","year":"2020","unstructured":"Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N, Zhao Y. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020, 10:2993-3036.","journal-title":"Am J Cancer Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S61146","article-title":"Hepatocellular carcinoma: a review","volume":"3","author":"Balogh J","year":"2016","unstructured":"Balogh J, Victor D 3rd, Asham EH, et al.. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016, 3:41-53. 10.2147\/JHC.S61146","journal-title":"J Hepatocell Carcinoma"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202205_28726","article-title":"A real-world study of Chinese hepatocellular carcinoma patients treated with TACE","volume":"26","author":"Hu HF","year":"2022","unstructured":"Hu HF, Sang YF. A real-world study of Chinese hepatocellular carcinoma patients treated with TACE. Eur Rev Med Pharmacol Sci. 2022, 26:3091-9. 10.26355\/eurrev_202205_28726","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/jcar.JCar_9_16","article-title":"Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis","volume":"16","author":"Ghouri YA","year":"2017","unstructured":"Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017, 16:1. 10.4103\/jcar.JCar_9_16","journal-title":"J Carcinog"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-017-1334-x","article-title":"LI-RADS categories: concepts, definitions, and criteria","volume":"43","author":"Santillan C","year":"2018","unstructured":"Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol (NY). 2018, 43:101-10. 10.1007\/s00261-017-1334-x","journal-title":"Abdom Radiol (NY)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226291","article-title":"Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC","volume":"14","author":"Erkan B","year":"2019","unstructured":"Erkan B, Meier J, Clark TJ, Kaplan J, Lambert JR, Chang S. Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC. PLoS One. 2019, 14:e0226291. 10.1371\/journal.pone.0226291","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02187-x","article-title":"Albumin-bilirubin grade as an alternative to Child-Pugh class for evaluating liver function within staging systems for hepatocellular carcinoma","volume":"16","author":"Guan MC","year":"2025","unstructured":"Guan MC, Ding Q, Zhao Q, et al.. Albumin-bilirubin grade as an alternative to Child-Pugh class for evaluating liver function within staging systems for hepatocellular carcinoma. Discov Oncol. 2025, 16:394. 10.1007\/s12672-025-02187-x","journal-title":"Discov Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig M","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al.. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022, 76:681-93. 10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.5604\/16652681.1184233","article-title":"Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm","volume":"15","author":"Richani M","year":"2016","unstructured":"Richani M, Kolly P, Knoepfli M, et al.. Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. Ann Hepatol. 2016, 15:82-90. 10.5604\/16652681.1184233","journal-title":"Ann Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.01.010","article-title":"Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal","volume":"80","author":"Trevisani F","year":"2024","unstructured":"Trevisani F, Vitale A, Kudo M, Kulik L, Park JW, Pinato DJ, Cillo U. Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal. J Hepatol. 2024, 80:661-9. 10.1016\/j.jhep.2024.01.010","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-260","article-title":"Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO)","volume":"10","author":"Lu J","year":"2021","unstructured":"Lu J, Zhao M, Arai Y, et al.. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surg Nutr. 2021, 10:661-71. 10.21037\/hbsn-21-260","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12030436","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: why, when, how?","volume":"12","author":"Kotsifa E","year":"2022","unstructured":"Kotsifa E, Vergadis C, Vailas M, et al.. Transarterial chemoembolization for hepatocellular carcinoma: why, when, how?. J Pers Med. 2022, 12:436. 10.3390\/jpm12030436","journal-title":"J Pers Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12380","article-title":"Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis","volume":"17","author":"Zou JH","year":"2016","unstructured":"Zou JH, Zhang L, Ren ZG, Ye SL. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis. 2016, 17:510-7. 10.1111\/1751-2980.12380","journal-title":"J Dig Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41701","article-title":"Comparison of the treatment response of drug-eluting bead transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"15","author":"Adel H","year":"2023","unstructured":"Adel H, Shazlee MK, Qamar S, Hyder SM, Razaque A. Comparison of the treatment response of drug-eluting bead transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma. Cureus. 2023, 15:e41701. 10.7759\/cureus.41701","journal-title":"Cureus"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-021-07834-9","article-title":"Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS","volume":"31","author":"Fan W","year":"2021","unstructured":"Fan W, Guo J, Zhu B, et al.. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. Eur Radiol. 2021, 31:8291-301. 10.1007\/s00330-021-07834-9","journal-title":"Eur Radiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i23.2561","article-title":"Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma","volume":"28","author":"Silk T","year":"2022","unstructured":"Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol. 2022, 28:2561-8. 10.3748\/wjg.v28.i23.2561","journal-title":"World J Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2024.09.002","article-title":"Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?","volume":"8","author":"Abdelhamed W","year":"2024","unstructured":"Abdelhamed W, Shousha H, El-Kassas M. Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?. Liver Res. 2024, 8:141-51. 10.1016\/j.livres.2024.09.002","journal-title":"Liver Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020314","article-title":"All you need to know about TACE: a comprehensive review of indications, techniques, efficacy, limits, and technical advancement","volume":"14","author":"Lanza C","year":"2025","unstructured":"Lanza C, Ascenti V, Amato GV, et al.. All you need to know about TACE: a comprehensive review of indications, techniques, efficacy, limits, and technical advancement. J Clin Med. 2025, 14:314. 10.3390\/jcm14020314","journal-title":"J Clin Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i46.17483","article-title":"Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma","volume":"20","author":"Ni JY","year":"2014","unstructured":"Ni JY, Sun HL, Chen YT, Luo JH, Chen D, Jiang XY, Xu LF. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma. World J Gastroenterol. 2014, 20:17483-90. 10.3748\/wjg.v20.i46.17483","journal-title":"World J Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00575-6","article-title":"Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate-stage hepatocellular carcinoma undergoing chemoembolization","volume":"23","author":"Bannangkoon K","year":"2023","unstructured":"Bannangkoon K, Hongsakul K, Tubtawee T. Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate-stage hepatocellular carcinoma undergoing chemoembolization. Cancer Imaging. 2023, 23:51. 10.1186\/s40644-023-00575-6","journal-title":"Cancer Imaging"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"Pinato DJ","year":"2017","unstructured":"Pinato DJ, Sharma R, Allara E, et al.. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017, 66:338-46. 10.1016\/j.jhep.2016.09.008","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00558-7","article-title":"Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates","volume":"23","author":"M\u00fcller L","year":"2023","unstructured":"M\u00fcller L, Gairing SJ, Foerster F, et al.. Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates. Cancer Imaging. 2023, 23:40. 10.1186\/s40644-023-00558-7","journal-title":"Cancer Imaging"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo M","year":"2020","unstructured":"Kudo M, Ueshima K, Ikeda M, et al.. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020, 69:1492-501. 10.1136\/gutjnl-2019-318934","journal-title":"Gut"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-023-02961-7","article-title":"Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"21","author":"Duan R","year":"2023","unstructured":"Duan R, Gong F, Wang Y, et al.. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2023, 21:120. 10.1186\/s12957-023-02961-7","journal-title":"World J Surg Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial","volume":"64","author":"Lencioni R","year":"2016","unstructured":"Lencioni R, Llovet JM, Han G, et al.. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol. 2016, 64:1090-8. 10.1016\/j.jhep.2016.01.012","journal-title":"J Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer T","year":"2017","unstructured":"Meyer T, Fox R, Ma YT, et al.. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017, 2:565-75. 10.1016\/S2468-1253(17)30156-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1159\/000522547","article-title":"Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Kudo M","year":"2022","unstructured":"Kudo M, Ueshima K, Ikeda M, et al.. Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma. Liver Cancer. 2022, 11:354-67. 10.1159\/000522547","journal-title":"Liver Cancer"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1159\/000531377","article-title":"A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial","volume":"13","author":"Kudo M","year":"2024","unstructured":"Kudo M, Ueshima K, Saeki I, et al.. A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial. Liver Cancer. 2024, 13:99-112. 10.1159\/000531377","journal-title":"Liver Cancer"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1177\/11795549221146648","article-title":"Effectiveness of c-TACE combined with sorafenib versus c-TACE monotherapy in advanced hepatocellular carcinoma: a retrospective study","volume":"17","author":"Liu S","year":"2023","unstructured":"Liu S, Han Y, Zhang Z, Wu F. Effectiveness of c-TACE combined with sorafenib versus c-TACE monotherapy in advanced hepatocellular carcinoma: a retrospective study. Clin Med Insights Oncol. 2023, 17:11795549221146648. 10.1177\/11795549221146648","journal-title":"Clin Med Insights Oncol"},{"key":"ref46","article-title":"Comparison of efficacy and safety between transarterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in the treatment of intermediate and advanced hepatocellular carcinoma","volume":"15","author":"Xu R","year":"2023","unstructured":"Xu R, Ji X, Pei X, Yu Y. Comparison of efficacy and safety between transarterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in the treatment of intermediate and advanced hepatocellular carcinoma. Am J Transl Res. 2023, 15:1117-28.","journal-title":"Am J Transl Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00574-7","article-title":"Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study","volume":"23","author":"Yin L","year":"2023","unstructured":"Yin L, Liu KC, Lv WF, et al.. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study. Cancer Imaging. 2023, 23:52. 10.1186\/s40644-023-00574-7","journal-title":"Cancer Imaging"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.102022","article-title":"Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma","volume":"46","author":"Li N","year":"2022","unstructured":"Li N, Yang P, Fang J. Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2022, 46:102022. 10.1016\/j.clinre.2022.102022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2020.02.125","article-title":"A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis","volume":"8","author":"Zhao S","year":"2020","unstructured":"Zhao S, Zhang T, Dou W, et al.. A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis. Ann Transl Med. 2020, 8:542. 10.21037\/atm.2020.02.125","journal-title":"Ann Transl Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn RS","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al.. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020, 382:1894-905. 10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1159\/000528272","article-title":"IMbrave150: Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in patients with Barcelona Clinic Liver Cancer stage B unresectable hepatocellular carcinoma: an exploratory analysis of the phase III study","volume":"12","author":"Kudo M","year":"2023","unstructured":"Kudo M, Finn RS, Galle PR, et al.. IMbrave150: Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in patients with Barcelona Clinic Liver Cancer stage B unresectable hepatocellular carcinoma: an exploratory analysis of the phase III study. Liver Cancer. 2023, 12:238-50. 10.1159\/000528272","journal-title":"Liver Cancer"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6353047","article-title":"Early experience of TACE combined with atezolizumab plus bevacizumab for patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria: a multicenter, single-arm study","volume":"2023","author":"Wang K","year":"2023","unstructured":"Wang K, Zhu H, Yu H, et al.. Early experience of TACE combined with atezolizumab plus bevacizumab for patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria: a multicenter, single-arm study. J Oncol. 2023, 2023:6353047. 10.1155\/2023\/6353047","journal-title":"J Oncol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.923263","article-title":"Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) for patients with medium-to-large hepatocellular carcinoma: A retrospective analysis of long-term outcome","volume":"26","author":"Liu W","year":"2020","unstructured":"Liu W, Xu H, Ying X, et al.. Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) for patients with medium-to-large hepatocellular carcinoma: A retrospective analysis of long-term outcome. Med Sci Monit. 2020, 26:e923263. 10.12659\/MSM.923263","journal-title":"Med Sci Monit"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1347675","article-title":"TACE-assisted multi-image guided radiofrequency ablation for the treatment of single hepatocellular carcinoma \u2264 5\u00a0cm: a retrospective study","volume":"14","author":"Xie Y","year":"2024","unstructured":"Xie Y, Lyu T, Song L, Tong X, Wang J, Zou Y. TACE-assisted multi-image guided radiofrequency ablation for the treatment of single hepatocellular carcinoma \u2264 5\u00a0cm: a retrospective study. Front Oncol. 2024, 14:1347675. 10.3389\/fonc.2024.1347675","journal-title":"Front Oncol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.26992","article-title":"Long-term outcomes of transcatheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early-stage hepatocellular carcinoma","volume":"4","author":"Zhang YJ","year":"2021","unstructured":"Zhang YJ, Chen MS, Chen Y, Lau WY, Peng Z. Long-term outcomes of transcatheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early-stage hepatocellular carcinoma. JAMA Netw Open. 2021, 4:e2126992. 10.1001\/jamanetworkopen.2021.26992","journal-title":"JAMA Netw Open"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2019.1692148","article-title":"The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"36","author":"Wang L","year":"2019","unstructured":"Wang L, Ke Q, Lin N, Huang Q, Zeng Y, Liu J. The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia. 2019, 36:1288-96. 10.1080\/02656736.2019.1692148","journal-title":"Int J Hyperthermia"},{"key":"ref57","article-title":"Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials","volume":"8","author":"Fu Y","year":"2015","unstructured":"Fu Y, Zhao X, Yun Q, et al.. Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015, 8:10388-400.","journal-title":"Int J Clin Exp Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020419","article-title":"Liver transplantation for hepatocellular carcinoma: how should we improve the thresholds?","volume":"14","author":"Shimamura T","year":"2022","unstructured":"Shimamura T, Goto R, Watanabe M, Kawamura N, Takada Y. Liver transplantation for hepatocellular carcinoma: how should we improve the thresholds?. Cancers (Basel). 2022, 14:419. 10.3390\/cancers14020419","journal-title":"Cancers (Basel)"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero JA","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, et al.. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018, 68:723-50. 10.1002\/hep.29913","journal-title":"Hepatology"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018, 69:182-236. 10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11648","article-title":"European Society of Organ Transplantation (ESOT) consensus report on downstaging, bridging and immunotherapy in liver transplantation for hepatocellular carcinoma","volume":"36","author":"Claasen MP","year":"2023","unstructured":"Claasen MP, Sneiders D, Rakk\u00e9 YS, et al.. European Society of Organ Transplantation (ESOT) consensus report on downstaging, bridging and immunotherapy in liver transplantation for hepatocellular carcinoma. Transpl Int. 2023, 36:11648. 10.3389\/ti.2023.11648","journal-title":"Transpl Int"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.634087","article-title":"Safety and efficacy of degradable starch microspheres transcatheter arterial chemoembolization (DSM-TACE) in the downstaging of intermediate-stage hepatocellular carcinoma (HCC) in patients with a Child-Pugh score of 8-9","volume":"12","author":"Minici R","year":"2021","unstructured":"Minici R, Ammendola M, Manti F, et al.. Safety and efficacy of degradable starch microspheres transcatheter arterial chemoembolization (DSM-TACE) in the downstaging of intermediate-stage hepatocellular carcinoma (HCC) in patients with a Child-Pugh score of 8-9. Front Pharmacol. 2021, 12:634087. 10.3389\/fphar.2021.634087","journal-title":"Front Pharmacol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24169","article-title":"Downstaging hepatocellular carcinoma: A systematic review and pooled analysis","volume":"21","author":"Parikh ND","year":"2015","unstructured":"Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl. 2015, 21:1142-52. 10.1002\/lt.24169","journal-title":"Liver Transpl"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.2800","article-title":"Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma","volume":"157","author":"Tabrizian P","year":"2022","unstructured":"Tabrizian P, Holzner ML, Mehta N, et al.. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022, 157:779-88. 10.1001\/jamasurg.2022.2800","journal-title":"JAMA Surg"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2024.01.062","article-title":"Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: the effectiveness of different particle sizes in downstaging and bridging in living donor liver transplantation","volume":"56","author":"Lim WX","year":"2024","unstructured":"Lim WX, Sim KS, Chen CL, Ou HY, Yu CY, Cheng YF. Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: the effectiveness of different particle sizes in downstaging and bridging in living donor liver transplantation. Transplant Proc. 2024, 56:596-601. 10.1016\/j.transproceed.2024.01.062","journal-title":"Transplant Proc"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro V","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, et al.. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996, 334:693-9. 10.1056\/NEJM199603143341104","journal-title":"N Engl J Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2020.01.06","article-title":"Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"6","author":"Bento de Sousa JH","year":"2021","unstructured":"Bento de Sousa JH, Calil IL, Tustumi F, da Cunha Khalil D, Felga GE, de Arruda Pecora RA, de Almeida MD. Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Transl Gastroenterol Hepatol. 2021, 6:11. 10.21037\/tgh.2020.01.06","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.08.035","article-title":"Up-to-7 criteria for hepatocellular carcinoma liver transplantation: a retrospective analysis of experiences","volume":"48","author":"Le\u00f3n D\u00edaz FJ","year":"2016","unstructured":"Le\u00f3n D\u00edaz FJ, P\u00e9rez Daga JA, S\u00e1nchez P\u00e9rez B, et al.. Up-to-7 criteria for hepatocellular carcinoma liver transplantation: a retrospective analysis of experiences. Transplant Proc. 2016, 48:2969-72. 10.1016\/j.transproceed.2016.08.035","journal-title":"Transplant Proc"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.02.018","article-title":"UNOS down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and meta-analysis of 25 studies","volume":"21","author":"Tan DJ","year":"2023","unstructured":"Tan DJ, Lim WH, Yong JN, et al.. UNOS down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and meta-analysis of 25 studies. Clin Gastroenterol Hepatol. 2023, 21:1475-84. 10.1016\/j.cgh.2022.02.018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.12.078","article-title":"Drug-eluting bead transarterial chemoembolization as bridge therapy for hepatocellular carcinoma before living-donor liver transplantation","volume":"48","author":"Yu CY","year":"2016","unstructured":"Yu CY, Ou HY, Weng CC, et al.. Drug-eluting bead transarterial chemoembolization as bridge therapy for hepatocellular carcinoma before living-donor liver transplantation. Transplant Proc. 2016, 48:1045-8. 10.1016\/j.transproceed.2015.12.078","journal-title":"Transplant Proc"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria","volume":"61","author":"Yao FY","year":"2015","unstructured":"Yao FY, Mehta N, Flemming J, et al.. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015, 61:1968-77. 10.1002\/hep.27752","journal-title":"Hepatology"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i12.1694","article-title":"Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization","volume":"7","author":"Orlacchio A","year":"2015","unstructured":"Orlacchio A, Chegai F, Merolla S, et al.. Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J Hepatol. 2015, 7:1694-700. 10.4254\/wjh.v7.i12.1694","journal-title":"World J Hepatol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-022-00708-w","article-title":"Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?","volume":"27","author":"Benk\u00f6 T","year":"2022","unstructured":"Benk\u00f6 T, K\u00f6nig J, Theysohn JM, Schotten C, Saner FH, Treckmann J, Radunz S. Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?. Eur J Med Res. 2022, 27:74. 10.1186\/s40001-022-00708-w","journal-title":"Eur J Med Res"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30413","article-title":"Alpha-fetoprotein decrease from > 1,000 to < 500 ng\/ml in patients with hepatocellular carcinoma leads to improved posttransplant outcomes","volume":"69","author":"Mehta N","year":"2019","unstructured":"Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-fetoprotein decrease from &gt; 1,000 to &lt; 500 ng\/ml in patients with hepatocellular carcinoma leads to improved posttransplant outcomes. Hepatology. 2019, 69:1193-205. 10.1002\/hep.30413","journal-title":"Hepatology"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026584","article-title":"Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma","volume":"100","author":"Jeong J","year":"2021","unstructured":"Jeong J, Park JG, Seo KI, et al.. Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma. Medicine (Baltimore). 2021, 100:e26584. 10.1097\/MD.0000000000026584","journal-title":"Medicine (Baltimore)"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v14.i2.90571","article-title":"Transarterial embolization is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation","volume":"14","author":"Lazzarotto-da-Silva G","year":"2024","unstructured":"Lazzarotto-da-Silva G, Scaffaro LA, Farenzena M, et al.. Transarterial embolization is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation. World J Transplant. 2024, 14:90571. 10.5500\/wjt.v14.i2.90571","journal-title":"World J Transplant"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03427-0","article-title":"Effect of skeletal muscle index on post-embolization syndrome of hepatocellular carcinoma after transarterial chemoembolization","volume":"24","author":"Wang X","year":"2024","unstructured":"Wang X, Wang J, Li J, et al.. Effect of skeletal muscle index on post-embolization syndrome of hepatocellular carcinoma after transarterial chemoembolization. BMC Gastroenterol. 2024, 24:333. 10.1186\/s12876-024-03427-0","journal-title":"BMC Gastroenterol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15075","article-title":"Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis","volume":"8","author":"Zhang X","year":"2017","unstructured":"Zhang X, Wang K, Wang M, Yang G, Ye X, Wu M, Cheng S. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget. 2017, 8:29416-27. 10.18632\/oncotarget.15075","journal-title":"Oncotarget"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan Y","year":"2023","unstructured":"Yuan Y, He W, Yang Z, et al.. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg. 2023, 109:1222-30. 10.1097\/JS9.0000000000000256","journal-title":"Int J Surg"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2022.0395","article-title":"Complications related to transarterial treatment of hepatocellular carcinoma: a comprehensive review","volume":"24","author":"Lee HN","year":"2023","unstructured":"Lee HN, Hyun D. Complications related to transarterial treatment of hepatocellular carcinoma: a comprehensive review. Korean J Radiol. 2023, 24:204-23. 10.3348\/kjr.2022.0395","journal-title":"Korean J Radiol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2016.09.024","article-title":"Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions","volume":"28","author":"Padia SA","year":"2017","unstructured":"Padia SA, Lewandowski RJ, Johnson GE, et al.. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol. 2017, 28:1-15. 10.1016\/j.jvir.2016.09.024","journal-title":"J Vasc Interv Radiol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1396964","article-title":"Hepatocellular carcinoma rupture following transarterial chemoembolization","volume":"32","author":"Singh Bhinder N","year":"2015","unstructured":"Singh Bhinder N, Zangan SM. Hepatocellular carcinoma rupture following transarterial chemoembolization. Semin Intervent Radiol. 2015, 32:49-53. 10.1055\/s-0034-1396964","journal-title":"Semin Intervent Radiol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e31828846de","article-title":"Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey","volume":"259","author":"Aoki T","year":"2014","unstructured":"Aoki T, Kokudo N, Matsuyama Y, et al.. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg. 2014, 259:532-42. 10.1097\/SLA.0b013e31828846de","journal-title":"Ann Surg"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S481301","article-title":"Multisequence MRI-based radiomic features combined with inflammatory indices for predicting the overall survival of HCC patients after TACE","volume":"11","author":"Zhou M","year":"2024","unstructured":"Zhou M, Zhang P, Mao Q, Shi Y, Yang L, Zhang X. Multisequence MRI-based radiomic features combined with inflammatory indices for predicting the overall survival of HCC patients after TACE. J Hepatocell Carcinoma. 2024, 11:2049-61. 10.2147\/JHC.S481301","journal-title":"J Hepatocell Carcinoma"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133488","article-title":"Prognostic relevance of objective response according to EASL criteria and mrecist criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis","volume":"10","author":"Vincenzi B","year":"2015","unstructured":"Vincenzi B, Di Maio M, Silletta M, et al.. Prognostic relevance of objective response according to EASL criteria and mrecist criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS One. 2015, 10:e0133488. 10.1371\/journal.pone.0133488","journal-title":"PLoS One"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-021-03375-3","article-title":"Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization: a two-center collaborative study","volume":"47","author":"Liu QP","year":"2022","unstructured":"Liu QP, Yang KL, Xu X, Liu XS, Qu JR, Zhang YD. Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization: a two-center collaborative study. Abdom Radiol (NY). 2022, 47:651-63. 10.1007\/s00261-021-03375-3","journal-title":"Abdom Radiol (NY)"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9604","article-title":"Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study","volume":"7","author":"Pinato DJ","year":"2016","unstructured":"Pinato DJ, Arizumi T, Jang JW, et al.. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study. Oncotarget. 2016, 7:44705-18. 10.18632\/oncotarget.9604","journal-title":"Oncotarget"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03135-8","article-title":"Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma","volume":"146","author":"Vogeler M","year":"2020","unstructured":"Vogeler M, Mohr I, Pfeiffenberger J, et al.. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020, 146:1033-50. 10.1007\/s00432-020-03135-8","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040791","article-title":"Embolotherapeutic strategies for hepatocellular carcinoma: 2020 update","volume":"12","author":"Kishore SA","year":"2020","unstructured":"Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic strategies for hepatocellular carcinoma: 2020 update. Cancers (Basel). 2020, 12:791. 10.3390\/cancers12040791","journal-title":"Cancers (Basel)"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010035","article-title":"Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria","volume":"13","author":"Li L","year":"2025","unstructured":"Li L, Xu X, Wang W, et al.. Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria. J Immunother Cancer. 2025, 13:e010035. 10.1136\/jitc-2024-010035","journal-title":"J Immunother Cancer"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"9","author":"Chen Y","year":"2024","unstructured":"Chen Y, Zhang J, Hu W, et al.. Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study. Signal Transduct Target Ther. 2024, 9:280. 10.1038\/s41392-024-01991-1","journal-title":"Signal Transduct Target Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/406183-optimizing-transarterial-chemoembolization-in-hepatocellular-carcinoma-current-strategies-innovations-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:23:12Z","timestamp":1761124992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/406183-optimizing-transarterial-chemoembolization-in-hepatocellular-carcinoma-current-strategies-innovations-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":91,"URL":"https:\/\/doi.org\/10.7759\/cureus.95128","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,22]]}}}